Home » Stocks » ADMP

Adamis Pharmaceuticals Corporation (ADMP)

Stock Price: $1.02 USD -0.04 (-3.77%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 151.86M
Revenue (ttm) 16.53M
Net Income (ttm) -49.39M
Shares Out 77.57M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $1.02
Previous Close $1.06
Change ($) -0.04
Change (%) -3.77%
Day's Open 1.05
Day's Range 1.01 - 1.06
Day's Volume 1,943,612
52-Week Range 0.38 - 2.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector of Election's certified results from the Company's 2...

5 days ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company's Board o...

1 week ago - Business Wire

Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?

Other stocks mentioned: ACST, AMPE, BIOL, ENZC, JAGX, NWBO
3 weeks ago - PennyStocks

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today issued the below letter to stockholders. *** July 1, 2021 Dear Stockholders, The Board of Directors (the "Board") appr...

3 weeks ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today issued the below letter to stockholders. June 28, 2021 Dear Stockholder, The Board of Directors (the "Board") apprecia...

3 weeks ago - Business Wire

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Are these Robinhood penny stocks the best to watch in 2021? The post Best Penny Stocks to Buy on Robinhood?

Other stocks mentioned: POAI, SOLO
1 month ago - PennyStocks

CTRN, SI, ADMP, ISBA, and DGICA have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2021

Other stocks mentioned: CTRN, DGICA, ISBA, SI
1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent t...

1 month ago - Business Wire

Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COV...

1 month ago - GlobeNewsWire

The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ: ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose. The agency's target action...

1 month ago - Benzinga

FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of Nove...

1 month ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has highlighted that the National Institutes of Health (NIH) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-1...

1 month ago - Benzinga

NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19”

1 month ago - GlobeNewsWire

Shares of Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) spiked higher in afternoon trading Thursday following some positive tidings on one of its pipeline assets. What Happened: Study of cell cultur...

1 month ago - Benzinga

NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19 NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiat...

1 month ago - GlobeNewsWire

SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, alle...

1 month ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $ADMP #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ADMP #investors--The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors

1 month ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $ADMP #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NASDAQ: ADMP...

1 month ago - Business Wire

Boston, Massachusetts--(Newsfile Corp. - May 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential violations of the federal securities laws by Adamis Pharma...

1 month ago - Newsfile Corp

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held...

2 months ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose. "Based on FDA fe...

2 months ago - Benzinga

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, alle...

2 months ago - GlobeNewsWire

SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, alle...

2 months ago - GlobeNewsWire

Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021

3 months ago - GlobeNewsWire

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, al...

3 months ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has provided an update on its marketing application's status seeking approval for Zimhi's high-dose naloxone injection product to treat opioid overdose....

3 months ago - Benzinga

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company's New Drug Application (NDA) relating to its ZIMHI™ ...

3 months ago - GlobeNewsWire

Adamis Pharmaceuticals shares were up in January on the news of its Covid-19 treatment trial, but ADMP stock has been sliding since. The post Wait for Q4 Earnings Before Making Any Move on Adamis Pharma...

3 months ago - InvestorPlace

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has reported positive data from lab studies conducted in animal models. The study showed that Tempol-treated hamsters challenged with COVID-19 infection achiev...

4 months ago - Benzinga

SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University o...

4 months ago - GlobeNewsWire

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety re...

5 months ago - GlobeNewsWire

U.S. Patent and Trademark Office has allowed a patent to one of the patent applications by Adamis Pharmaceuticals Corp (NASDAQ: ADMP) related to its ZIMHI high-dose naloxone injection product candidate,...

5 months ago - Benzinga

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating...

5 months ago - GlobeNewsWire

SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, ...

5 months ago - GlobeNewsWire

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therap...

5 months ago - GlobeNewsWire

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therap...

5 months ago - GlobeNewsWire

SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of ...

5 months ago - GlobeNewsWire

Adamis Pharmaceuticals finished 2020 with some Malheur with the company receiving its second CRL for ZIMHI. However, the company is a making a strong comeback thus far in 2021. Adamis plans to appeal th...

6 months ago - Seeking Alpha

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focu...

Other stocks mentioned: FLDM, SEEL, BCRX
6 months ago - Benzinga

Adamis Pharma (ADMP) stock is taking off on Friday after a week of positive news for the company, including a deal with Walgreens. The post ADMP Stock: 4 Things to Know About Adamis Pharma Today as Shar...

6 months ago - InvestorPlace

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members of the Walg...

6 months ago - GlobeNewsWire

Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.

6 months ago - Zacks Investment Research

Adamis Pharma (ADMP) stock is taking off on Wednesday following news of its possible treatment for the novel coronavirus. The post ADMP Stock Alert: The Covid-19 Treatment News That Has Adamis Pharma Sh...

6 months ago - InvestorPlace

SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigation...

6 months ago - GlobeNewsWire

Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it recei...

8 months ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

About ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candida... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Dennis Carlo
Employees
116
Stock Exchange
NASDAQ
Ticker Symbol
ADMP
Full Company Profile

Financial Performance

In 2020, ADMP's revenue was $16.53 million, a decrease of -25.26% compared to the previous year's $22.11 million. Losses were -$49.39 million, 79.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ADMP stock is "Buy." The 12-month stock price forecast is 1.00, which is a decrease of -1.96% from the latest price.

Price Target
$1.00
(-1.96% downside)
Analyst Consensus: Buy